Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Thrombosis Stories

2011-07-01 16:23:00

RARITAN, N.J., July 1, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. To view the multimedia assets associated with this release, please click:...

2011-07-01 14:00:00

RARITAN, N.J., July 1, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. "The approval of once-daily XARELTO® tablets will provide a new...

b6bf1b2a6939f301a03df3066db69dc8
2011-06-29 09:43:59

If you're looking for a place to go this summer that is really active, don't go to Lexington, Kentucky. A new ranking of the most sedentary cities in the world by Men's Health magazine has placed the "ËœThoroughbred Capital of the World' at the bottom of the heap. Along with Lexington, the ranking also puts Indianapolis, Indiana, Jackson, Mississippi, Charleston, West Virginia and Oklahoma City, Oklahoma as the 5 most sedentary cities respectively, according to Men's Health. The...

2011-06-23 23:05:29

Outpatient care for certain low-risk patients with pulmonary embolism (PE) can be safely and effectively used in place of inpatient care, according to a randomized, multi-center study in 19 emergency departments. The findings, published June 23 online in the Lancet, support current practice guidelines that are rarely followed by physicians. "This is the most rigorous study to date to compare inpatient and outpatient care for a selected group of stable patients with pulmonary embolism," said...

2011-06-15 00:00:26

The US Drug Watchdog is calling its Yaz, Yasmin, or the generic version of these birth control pills called Ocella, their most important women's health care initiative ever. The group says, "If a user of the birth control pills called Yaz, Yasmin, or the generic version Ocella has had a pulmonary embolism, a heart attack, stroke, blood clotting, or other severe medical complications, while taking these birth control pills, we want to know about it. We are hearing horror stories from the...

2011-06-14 13:41:10

Introducing stabilization of vulnerable plaques as part of secondary prevention would offer the opportunity to wipe out half of coronary events The European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology has published a position paper to raise the profile of vulnerable plaques and the need for greater use of therapies to promote plaque stabilisation. The position paper, published online today in Thrombosis and Haemostasis, is also calling for more research...

2011-06-04 07:00:00

PARIS, June 4, 2011 /PRNewswire-FirstCall/ -- - Results of Phase III SAVE-ONCO Study Selected for "Best of ASCO 2011" - - Venous Thrombo-embolism Affects Up to 1 in 5 Cancer Patients And Chemotherapy Further Increases this Risk Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of...

2011-06-04 07:00:00

BRIDGEWATER, N.J., June 4, 2011 /PRNewswire/ -- Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%(i), meeting the study primary endpoint (respectively 1.2%...

2011-05-31 15:22:19

In a nationwide study, researchers at the Centre for Primary Health Care Research in Malmö, Sweden, have mapped the significance of hereditary factors in venous thromboembolism. Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmö have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by...

2011-05-31 07:00:00

WEST HILLS, California, May 31, 2011 /PRNewswire/ -- Medical Compression Systems (MCS), which is involved in the non-invasive medical device industry and traded on the TASE, announced today that it has received FDA clearance to market the ActiveCare+Dx (temporary name) device developed on the basis of its flagship product, ActiveCare+S.F.T.(R) The new product is the only one on the market which integrates venous obstruction prevention and detection capacities whereby both operations...